Objectives: Ovarian hormones have been shown to regulate body weight, intra-abdominal fat accumulation and plasma level of cytokines. The aim of this study was to investigate the effect of estrogen replacement therapy on visceral adipose tissue, plasma level of apelin, lipid profiles, and glucose in ovariectomized (OVX) rats. Methods: Thirty female Wistar rats were divided into OVX (n = 20) and sham (n = 10) groups. OVX rats were subdivided into estrogen replacement therapy (OVX+est; n = 10) receiving 17 β -estradiol valerates (30 μ g/kg, s.c., 5 day/week, for eight weeks), and vehicle control group receiving sesame oil same as experiment group (OVX+ses oil; n = 10). After the treatments, all groups were sacrificed and blood samples were collected, visceral fats were taken from the abdominal cavity and weighed immediately. Apelin were measured using enzyme-linked immunosorbent assay kits. Lipid profiles and glucose were measured using the enzymatic colorimetric method. Data were analyzed with one-way analysis of variance and (P < 0.05) determined as the statistical significance level. Results: After eight weeks, body weight, body mass index (BMI), visceral fat, apelin and lipid profiles (P < 0.01) were increased significantly in OVX rats compared to sham group. Treatment with estrogen leads to significant reduction in body weight and BMI (P < 0.05), there was no significant change in serum apelin level in OVX+est rats compared to OVX+ses. Conclusions: These results suggest that estradiol replacement therapy successfully attenuated some of the metabolic syndrome components, and apelin does not probably stand as a mediator of these physiological functions. (J Menopausal Med 2017;23:182-189)
Introduction
Obesity is now recognized as a major public health problem that constitutes a risk factor for life-threatening diseases such as type 2 diabetes and cardiovascular disease (CVD), as well as some types of cancer. 1 These disorders represent major causes of morbidity and mortality in industrialized countries and are increasing problems in developing countries as well. 2 Obesity as the most common disorders in climacteric women occurs in approximately 65% of them 3 due to alterations in visceral adipose tissue metabolism. 4, 5 Menopause is associated with a rise in follicle-stimulating hormone and luteinizing hormone levels and a fall in estrogen. 6~9 Women have more body fat compared to men, and there is a gender-specific difference in fat distribution. In women, adipose Existence of apelin and its receptor in various tissues of human and mice such as: hypothalamus, anterior pituitary, endothelial vessels, heart, lungs, stomach, kidney, mammary glands, thyroid, ovarian, colon mucus, pancreas, adipose tissue, liver and muscle reveal the widespread role of this hormone.
18~29
The hormone regulates adipose tissue' s growth and has a role in the process of chronic inflammation caused by increased adipose tissue and stress. 24, 28 Apelin upregulates sex steroids, insulin, tumor necrosis factor-α and growth hormone in adipose tissues of human and mice. 19 ,23~29 This cytokine is involved in regulation of fluids and food intake in the hypothalamus 22 and increases in apelin concentration results in energy consumption.
30~32
Regarding the fact that visceral fat is the source of adipokines, more notably, apelin, we hypothesized that estrogen deficiency might be one possibility for apelin level reduction and consequently visceral fat accumulation with other clusters of metabolic syndrome components.
To our knowledge relationship between plasma apelin concentration and estrogen treatment has not been studied yet. Therefore, the purpose of this study was to determine the effect of estrogen replacement therapy on visceral fat, serum apelin level. To approach these goals, we used OVX rats as a model of menopause.
33~37

Materials and Methods
Female Wistar rats (n = 30), weighing 180 to 200 g (2 months of age) were used in this study. Except for sham group, all animal underwent OVX surgery according to the technique described by Babaei et al.. 33 For surgery, rats were anesthetized using a mixture of ketamine-xylazine (61.5-7.6 mg/kg, i.p.). Animals were housed four per cage and fed standard pellet rat chow and had free access to tap water. oil. All rats were weighed twice a week, between 09:00 and 11:00 to yield a weekly weight for each animal, two weights were averaged. To measure the food intake, an equal amount of food (20 g/day/rat) was given to all rats and their consumption was measured the following day by subtracting the remaining uneaten food from the total given one. All experimental groups had initially similar mean body mass and were treated similarly in terms of daily manipulations.
Body weight, food intake, and visceral fat were measured using the accurate to 0.1 g scale (Sartorius, Goettingen, Germany). ).
2) Blood sample
The food was removed from the animal' s cage at least 24 hours before scarification. After complete anesthesia, the abdominal cavity was rapidly opened and blood samples were drawn from the inferior vena cava. The serum was immedi- 
3) Statistical analysis
All data are presented as mean ± standard error (SE) before statistical analysis, normal distribution and homogeneity of the variances were tested by K-S test. Statistical comparisons between groups were performed by one-way analysis of variance test, followed by Tukey' s post-hoc test.
Levels of statistical significance were set at P < 0.05.
Results
Two weeks after OVX, visceral fat (P = 0.006) and body weight (P = 0.001) of OVX group were significantly increased compared with the sham group and remained elevated even after 8 weeks of surgery (P = 0.02, P = 0.004) respectively (Table 1) .
Serum glucose, TC (P = 0.004) and HDL-C (P = 0.027)
and LDL-C (P = 0.022) also showed elevation after two weeks of OVX.
No significant difference was observed in visceral fat, blood lipids and plasma apelin concentration between
OVX+est and OVX+ses oil groups after eight weeks of treatment. However, estrogen therapy reduced body weight compared with the OVX+ses oil group (Table 2) . 
Discussion
Our results showed a significant difference in body weight, height, BMI, visceral fat, weight, glucose level, blood lipid profile, and serum apelin between the OVX and sham groups, two weeks after surgery. These findings partly are in agreement with the results of our previous study 40 and
Al-Wahaibi and colleagues 41 indicating the significant increase in body weight of OVX rats after one month.
Ten weeks follow-up in our study showed that increase in body weight and visceral fat in OVX rats remained elevated compared to the control group. This is in agreement with the findings of several studies showed an increase in visceral fat after hypoestrogenism. 41~43 OVX may stimulate adipocyte hypertrophy and increased levels of epidermal growth factor, therefore OVX rats will be promoting obesity.
38,39
The results of 8-week estrogen therapy in the present study revealed that a significant reduction in body weight and BMI. While no significant difference was observed in Although the mechanisms of estrogen on body weight has not been fully understood, but the study carried out by Ryan et al. 47 showed that ovarian steroid hormones involved in the regulation of obese gene and corticosterone hormone.
According to D' Eon et al. 48 estrogen therapy leads to weight reduction. In the present study, a significant reduction in body weight after estrogen therapy is not in parallel with a reduction in visceral fat. The data found in our study on visceral fat is consistent with Ryan et al. 47 and Sites et al. 49 in postmenopausal women after hormone replacement therap. However, some studies showing contradictory results of estrogen on visceral fat in postmenopausal women 49~51 and OVX rats as well. 42 D' Eon et al. 48 were reported a reduction in visceral adipose tissue and adipocytes size in OVX rats after estrogen therapy. They found increased rate of adipocytes lipolysis and down-regulation of related genes, Studies have shown that hypoestrogenism coincides with hyperlipidemia, hyperinsulinemia, and hypertension, the most important components of metabolic syndrome. 54 On the other hand, increasing in cytokines such as apelin is associated with hypertension, heart failure, obesity, 55, 56 hyperglycemia and atherogenic effects 57, 58 and also according to studies Apelin can be used as a specific marker for insulin sensitivity and lipid profile and this adipokine might play a role in the pathogenesis of polycystic ovarian syndrome.
59~64
No significant change in serum apelin of OVX rats after estrogen replacement indicates that serum apelin concentration was found to be regulated by other factors such as nutrition, growth hormone, cortisol, 29 and also liver function 65 rather than estrogen per se. Future studies with long-term intervention are suggested to clarify the relationship between the cytokine apelin and estrogen considering molecular signaling.
Conclusion
In conclusion, estrogen therapy has beneficial effects on weight loss probably through other cytokines rather apelin.
From a clinical point of view estrogen in low dose, can be considered as a preventive pharmacologic tool in menopausal women.
